Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts
Authors
Keywords
Erythropoietin, Erythropoietin receptor, Vascular endothelial growth factor receptor, Colon cancer
Journal
MOLECULAR AND CELLULAR BIOCHEMISTRY
Volume 421, Issue 1-2, Pages 1-18
Publisher
Springer Nature
Online
2016-08-20
DOI
10.1007/s11010-016-2779-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Erythropoietin suppresses the activation of pro-apoptotic genes in head and neck squamous cell carcinoma xenografts exposed to surgical trauma
- (2014) Gustaf Lindgren et al. BMC CANCER
- Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance
- (2014) E. Rozengurt et al. MOLECULAR CANCER THERAPEUTICS
- Effect of erythropoietin, 5-fluorouracil and SN-38 on the growth of DLD-1 cells
- (2014) Anna Tankiewicz-Kwedlo et al. Pharmacological Reports
- Akt and mTOR mediate programmed necrosis in neurons
- (2014) Q Liu et al. Cell Death & Disease
- Erythropoietin Activates Cell Survival Pathways in Breast Cancer Stem-like Cells to Protect Them from Chemotherapy
- (2013) M. Todaro et al. CANCER RESEARCH
- Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study
- (2013) Maria Trincavelli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Preoperative administration of erythropoietin stimulates tumor recurrence after surgical excision of colon cancer in mice by a vascular endothelial growth factor–independent mechanism
- (2013) Marta Pascual et al. JOURNAL OF SURGICAL RESEARCH
- Tissue protection by erythropoietin: new findings in a moving field
- (2013) Masaomi Nangaku KIDNEY INTERNATIONAL
- Jacaric acid, a linolenic acid isomer with a conjugated triene system, has a strong antitumor effect in vitro and in vivo
- (2012) Nahoko Shinohara et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Association of symptoms of colon cancer patients with tumor location and TNM tumor stage
- (2012) Kristin K. Alexiusdottir et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Expression of erythropoietin and its receptor increases in colonic neoplastic progression: The role of hypoxia in tumorigenesis
- (2011) Zoltan Gombos et al. Indian Journal of Pathology and Microbiology
- Autocrine/paracrine erythropoietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells
- (2011) Tania V. Lopez et al. INTERNATIONAL JOURNAL OF CANCER
- Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes
- (2011) Enrico Balleari et al. LEUKEMIA RESEARCH
- Lack of expression and function of erythropoietin receptors in the kidney
- (2011) Steve Elliott et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Absence of functional EpoR expression in human tumor cell lines
- (2010) S. Swift et al. BLOOD
- Erythropoietin-Induced Activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK Pathways Promotes Malignant Cell Behavior in a Modified Breast Cancer Cell Line
- (2010) Z. Shi et al. MOLECULAR CANCER RESEARCH
- The erythropoietin receptor in normal and cancer tissues
- (2008) Wolfgang Jelkmann et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- PI3K/Akt: getting it right matters
- (2008) T F Franke ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now